Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease (ADICROHN3)
1. juni 2026 oppdatert av: Assistance Publique Hopitaux De Marseille
The ADICROHN-3 study is a prospective, multicenter, open-label cohort study.
Its design is supported by the following elements:
- The results of the ADICROHN pilot study (EudraCT No. 2013-002602-31) and our 3-year study, which demonstrate an excellent safety profile with a promising efficacy signal.
- Data from the literature confirming that cryopreservation of FVS does not compromise the clonogenic and differentiation potential of mesenchymal progenitors, nor its regenerative effect.
- The ongoing ADICROHN-2 study (PHRC N 2019; EudraCT No. 2019-001948-21) confirming the feasibility of patient recruitment, mastery of the therapeutic approach, and the absence of adverse events related to the experimental treatment.
- The opportunity for a second FVS injection for patients initially treated but who did not respond to the treatment.
- The opportunity for a first FVS injection in patients in the placebo arm, thereby providing access to an innovative therapy available to patients included in this trial who are untreated and remain refractory to standard care.
To avoid compromising the results of the ongoing ADICROHN-2 study, enrolled patients will remain blinded to the treatment arm to which they belonged in the ADICROHN-2 study.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
25
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Marseille, Frankrike
- Rekruttering
- APHM Hôpital Nord
-
Ta kontakt med:
- Dr GUILLO
- Telefonnummer: +33 0491968737
- E-post: lucas.guillo@ap-hm.fr
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- (1) Signing of a consent form.
- (2) Patients with Crohn's disease diagnosed at least 6 months prior, in accordance with clinical, endoscopic, histological, and/or radiological criteria.
- (3) Patients previously enrolled in or treated as part of the ADICROHN 2 study.
- (4) Non-active or mildly active luminal Crohn's disease, defined by a CDAI score ≤ 220.
- (5) Patients who failed to respond to the ADICROHN-2 protocol, defined by the persistence of anoperineal fistula(s) at the end of the ADICROHN-2 study and their persistence at the time of enrollment.
- (6) Patients who achieved success (combined remission) at the end of the ADICROHN-2 study but who have a recurrence of anoperineal fistula(s) at the time of enrollment.
- (7) Sufficient quantity of cryopreserved cells to allow for the innovative treatment, based on the number of fistulas to be treated.
- (8) Patients over 18 years of age.
- (9) Good general health based on medical history and clinical examination.
- (10) Women of childbearing age must have a negative pregnancy test (serum or urine; detection threshold: 25 mIU hCG/ml). Patients of both sexes must use a reliable method of contraception.
- (11) Enrollment in a social security program.
Exclusion Criteria:
- (1) Active, primarily luminal Crohn's disease requiring immediate treatment.
- (2) Patients who experienced intolerance to the advanced therapy medicinal product during the ADICROHN-2 study.
- (3) Presence of an abscess or collections > 2 cm at the time of enrollment, unless this issue is resolved during the fistula preparation period.
- (4) Rectal and/or anal stenosis and/or active proctitis resulting in a limitation of the surgical procedure.
- (5) Patients currently receiving corticosteroids or who have received them within the four weeks prior to the injection of the investigational product.
- (6) Malignant tumors or a history of malignant tumors within the past 5 years.
- (7) Congenital or acquired immunodeficiency.
- (8) Contraindications to local anesthetics and gadolinium (MRI contrast agent).
- (9) Contraindications to MRI: metallic foreign bodies (ferromagnetic material) and metallic implants (pacemakers, heart valves, vascular clips, surgical clips or staples, cochlear implants, any implanted electronic medical device or material [e.g., insulin pump], orthopedic medical prostheses.
- (10) Treatment with darvadstrocel administered < 6 months prior to enrollment)
- (11) Contraindications to general anesthesia.
- (12) BMI < 18 kg/m² to ensure an adequate amount of abdominal adipose tissue or other subcutaneous adipose tissue accessible via manual liposuction.
- (13) Coagulation disorders that contraindicate surgery.
- (14) Known hypersensitivity to human albumin.
- (15) Participation in another clinical trial (excluding observational studies).
- (16) Persons protected under Articles L1121-5, L1121-6, and L1121-8 of the Public Health Code (pregnant or breastfeeding women, persons deprived of liberty by judicial decision, persons in situations of social vulnerability, adults who are legally incapacitated or unable to give informed consent).
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: treatment arm
injection of thawed SVF
|
injection of thawed SVF, collected in ADICROHN 2
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tidsramme: 6 months
|
absence of local infectious complications, defined by the absence of local signs of inflammation: pain, and/or erythematous plaque, and/or swelling or induration.
|
6 months
|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tidsramme: 6 months
|
absence of systemic infectious complications, defined as the absence of systemic signs of infection: fever, chills, mottling, hypotension.
|
6 months
|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tidsramme: 6 months
|
absence of any worsening of anal incontinence compared with the pre-treatment assessment, as measured by the Wexner index
|
6 months
|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tidsramme: 6 months
|
absence of any other adverse events considered to be potentially related to the experimental treatment.
|
6 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
30. desember 2025
Primær fullføring (Antatt)
29. juni 2028
Studiet fullført (Antatt)
29. juni 2028
Datoer for studieregistrering
Først innsendt
31. mars 2026
Først innsendt som oppfylte QC-kriteriene
1. juni 2026
Først lagt ut (Faktiske)
5. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
5. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RCAPHM22_0449
- 2024-519740-32-00 (Ctis)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .